Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07426484 · ClinicalTrials.gov registry record · Phase 4
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
A Phase 4 study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT07426484: Clinical Trial Phase 4 study, sponsored by Dana-Farber Cancer Institute.
NCT07426484 is a Phase 4 study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 80 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07426484, a Phase 4 study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
Primary Outcome
BORR is defined as the proportion of participants whose best overall responses are complete metabolic response (CMR) and partial metabolic response (PMR). Per PERCIST 1.0 for target lesions, CMR is visual disappearance of all metabolically active tumor, and PMR is at least a 30% decrease in SUL peak (minimum 0.8-unit decrease) in the lesion with greatest uptake, not necessarily the same lesion.
Interventions
- DRUG Sirolimus
- DRUG Everolimus
- DRUG Prednisone
- DRUG Cosibelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-07 |
| Est. Completion | 2032-12-15 |
| Phase | Phase 4 |
What is known before NCT07426484 opens enrollment
NCT07426484 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 4 interventions - of which Sirolimus is the first listed.
NCT07426484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07426484 about?
NCT07426484 is a clinical study titled "Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy". This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
What is the current status of trial NCT07426484?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2026-07. Estimated completion is 2032-12-15.
What interventions are being tested in trial NCT07426484?
The interventions under investigation include: Sirolimus (DRUG), Everolimus (DRUG), Prednisone (DRUG), Cosibelimab (DRUG).
Who is sponsoring clinical trial NCT07426484?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07426484's enrollment target sits among peer trials
80 946th of 2000 higher than 1,021 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia